Compare LZB & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | NEO |
|---|---|---|
| Founded | 1927 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | LZB | NEO |
|---|---|---|
| Price | $38.78 | $11.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.50 | $11.38 |
| AVG Volume (30 Days) | 394.6K | ★ 1.9M |
| Earning Date | 02-17-2026 | 02-17-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $2,107,357,000.00 | $709,162,000.00 |
| Revenue This Year | $2.36 | $10.86 |
| Revenue Next Year | $3.57 | $9.70 |
| P/E Ratio | $17.97 | ★ N/A |
| Revenue Growth | 1.78 | ★ 10.10 |
| 52 Week Low | $29.03 | $4.72 |
| 52 Week High | $48.13 | $14.73 |
| Indicator | LZB | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 37.64 |
| Support Level | $35.76 | $11.24 |
| Resistance Level | $39.03 | $12.68 |
| Average True Range (ATR) | 0.95 | 0.51 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 61.97 | 5.85 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.